Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MET-3 by Nubiyota for Hypertriglyceridemia: Likelihood of Approval
MET-3 is under clinical development by Nubiyota and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs...